Characterizing the severe reactions of Parenteral Vitamin K1

Clinical and Applied Thrombosis/Hemostasis

Volumn 24, Issue 1, 2018, Pages 5-12

  Britt, Rachel B ^a,b   Brown, Jamie N ^b  

^a DURHAM VA HEALTH CARE SYSTEM   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Adverse drug reaction; Anaphylactoid; Anaphylaxis; Phytonadione; Safety; Vitamin K1

Indexed keywords

CREMOPHOR; PHYTOMENADIONE; ANTICOAGULANT AGENT; ANTIDOTE;

ADVERSE DRUG REACTION; ANAPHYLAXIS; ANTICOAGULATION; BRADYCARDIA; BRONCHOSPASM; CHEST TIGHTNESS; CYANOSIS; DEATH; DIAPHORESIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; FEVER; HEART ARREST; HUMAN; HYPOTENSION; INCIDENCE; PRIORITY JOURNAL; RESPIRATORY ARREST; REVIEW; SHOCK; TACHYCARDIA; BLOOD; CHEMICALLY INDUCED; FEMALE; MALE;

ANAPHYLAXIS; ANTICOAGULANTS; ANTIDOTES; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; VITAMIN K 1;

EID: 85045689886     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616674825     Document Type: Review

References (39)

1. Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am. 2000; 14(2):339-353.
2. World Health Organization International Agency for Research on Cancer (IARC). Vitamin K substances: IARC monograph. IARC Monogr Eval Carcinog Risks Hum. 2000;76:417-486.
3. Brayfield A, ed. Vitamin K substances. In: Martindale: The Complete Drug Reference [via LexiComp Online]. London, England: Royal Pharmaceutical Society/Pharmaceutical Press; 2013.
4. Vitamin K1 (phytonadione injectable emulsion) [package insert]. Lake Forest, IL: Hospira; 2004.
5. Mephyton (phytonadione tablets) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2012.
6. Holbrook A1, Schulman S, Witt DM, et al: American College of Chest Physicians. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2): e152S-e184S.
7. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M; British Committee for Standards in Haematology Guideline. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160(1):35-46.
8. Keeling D, Baglin T, Tait C, et al; British Committee for Standards in Haematology Guideline. Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol. 2011;154(3):311-324.
9. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29(2):171-181.
10. Anticoagulants, thrombolytic agents, and anti-platelet drugs. In: Aronson JK, ed. Meyler’s Side Effects of Cardiovascular Drugs. San Diego, CA: Elsevier Science; 2009:449-556.
11. Aronson JK. Meyler’s Side Effects of Drugs: An Encyclopedia of Adverse Reactions and Interactions. 15th ed. San Diego, CA: Elsevier Science; 2006.
12. Howland MA. Antidotes in depth: vitamin K1. In: Goldfrank L, Flomenbaum N, Lewin N, Howland MA, Hoffman R, Nelson L, eds. Goldfrank’s Toxicologic Emergencies. 10th ed. New York, NY: McGraw-Hill; 2015.
13. Institute for Safe Medication Practices. Medication Safety Alert! Acute Care Edition. Safe practice recommendations for using vitamin K1 to reverse excessive warfarin anticoagulation.https://www.ismp.org/newsletters/acutecare/articles/19991103.asp. Published November 1999. Accessed October 11, 2016.
14. Solensky R, Khan DA, eds. Joint Task Force on Practice Parameters for Allergy and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010; 105(273):e1-e78.
15. Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitaminK. J Thromb Thrombolysis. 2001;11(2):175-183.
16. Pereira SP, Williams R. Adverse events associated with vitamin K1: results of a worldwide postmarketing surveillance. Pharmacoepidemiol Drug Saf. 1998;7(3):173-182.
17. Shields RC, McBane RD, Kuiper JD, Li H, Heit JA. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc. 2001; 76(3):260-266.
18. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5- year retrospective review. Ann Allergy Asthma Immunol. 2002; 89(4):400-406.
19. Cragun J, Baggs J, Rollins C, Chambers S. Hypersensitivity reaction to parenteral nutrition after severe hypersensitivity reaction to paclitaxel: a case report. AmJ ClinExpObstet Gynecol. 2013;1(1):69-75.
20. Jethava A, Mathew J, Dasanu C. Anaphylactic reactions with intravenous vitamin K: lessons from the bedside. Conn Med. 2012;76(9):549-550.
21. Wjasow C, McNamara R. Anaphylaxis after low dose intravenous vitamin K. J Emerg Med. 2003;24(2):169-172.
22. Riegert-Johnson DL, Kumar S, Volcheck GW. A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K(1)). Bone Marrow Transplant. 2001;28(12):1176-1177.
23. Songy KA, Layon AJ. Vitamin K-induced cardiovascular collapse. J Clin Anesth. 1997;9(6):514-519.
24. Corrallo CE, Gillet M. Anaphylactic shock following intravenous vitamin K1. Aust J Hosp Pharm. 1997;27(2):146-147.
25. Martinez-Abad M, Delgado F, Palop V, Morales-Olivas FJ. Vitamin K1 and anaphylactic shock. DICP Ann Pharmacother. 1991; 25(7-8):871-872.
26. de la Rubia J, Grau E, Montserrat I, Zuazu I, Payá A. Anaphylactic shock and vitamin K1. Ann Intern Med. 1989;110(11):943.
27. Anderson TH, Hindsholm KB, Fallingborg J. Severe complication to phytomenadione after intramuscular injection in woman in labor. Case report and review of literature. Acta Obstet Gynecol Scand. 1989;68(4):381-382.
28. Lefrere JJ, Girot R. Acute cardiovascular collapse during intravenous vitamin K1 injection. Thromb Haemost. 1987;58(2):790.
29. Havel M, Müller M, Graninger W, Kurz R, Lindemayr H. Tolerability of a new vitamin K1 preparation for parenteral administration to adults: one case of anaphylactoid reaction. Clin Ther. 1987;9(4):373-379.
30. Rich EC, Drage CW. Severe complication of intravenous phytonadione therapy two cases, with one fatality. Postgrad Med. 1982; 72(5):303-306.
31. Barash P, Kitahata LM, Mandel S. Acute cardiovascular collapse after intravenous phytonadione. Anesth Analg. 1976;55(2): 304-306.
32. Beamish RE, Storrie VM. Severe haemolytic reaction following the intravenous administration of emulsified vitamin K1 (Mephyton). Can Med Assoc J. 1956;74(2):149-152.
33. Koklu E, Taskale T, Koklu S, Ariguloglu EA. Anaphylactic shock due to vitamin K in a newborn and review of literature. J Matern Fetal Neonatal Med. 2014;27(11):1180-1181.
34. Aziz NA, Kamaruddin Z, Hassan Y, et al. Vitamin K induced anaphylactic shock. J Pharm Technol. 1996;12(5):214-216.
35. Hopkins CS. Adverse reaction to a cremophor-containing preparation of intravenous vitamin K. Intensive Ther Clin Monit. 1988;9:254-255.
36. Mi YN, Ping NN, Xiao X, Zhu YB, Liu J, Cao YX. The severe adverse reaction to vitamin K1 injection is anaphylactoid reaction but not anaphylaxis. PLoS One. 2014;9(3):e90199.
37. Barnette RE, Wendling WW, Schweiger JW, et al. Intravenous vitamin K1 prior to orthotopic heart transplantation: effects in vivo and in vitro. Acta Anaesthesiol Scand. 1997;41(1 pt 1): 78-83.
38. Tirapelli CR, Resstel LB, de Oliveira AM, Correˆa FM. Mechanisms underlying the biphasic effect of vitamin K1 (phylloquinone) on arterial blood pressure. J Pharm Pharmacol. 2008;60(7): 889-893.
39. Drolet B, Emond A, Fortin V, et al. Vitamin K modulates cardiac action potential by blocking sodium and potassium ion channels. J Cardiovasc Pharmacol Ther. 2000;5(4):267-273.